Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsPeter Kwong, Barney Graham, Jason McLellan, Jeffrey Boyington, Ivelin Stefanov Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Marie Pancera, Cinque Soto, Sanjay Srivatsan, Baoshan Zhang
Estimating the term…
Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.
An isolated immunogen, comprising:
An epitope-scaffold protein, comprising a heterologous scaffold protein linked to a polypeptide comprising a RSV F protein prefusion epitope, wherein monoclonal antibody D25 or AM22 specifically binds to the epitope-scaffold protein.
A recombinant RSV F protein comprising cysteine residues at positions 155 and 290, wherein the RSV F protein induces an immune response to RSV F protein in a subject.
Dependencies are inferred from the claim text.